ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 270

Use of Drug Combinations in Patients with Osteoarthritis: A Population-Based Cohort Study

Daniel Prieto-Alhambra1 and Rosa Morros2, 1Internal Medicine; Primary Care; NDORMS Dept; MRC Lifecourse Epidemiology Unit, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, 2Primary Care, IDIAP Jordi Gol; Institut Català de la Salut, Spain

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Economics, medication, osteoarthritis and safety

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

TITLE: “Use of drug combinations in patients with osteoarthritis: a population-based cohort study.”

Background/Purpose:

Patients affected with osteoarthritis (OA) use different drugs in search for relief. We used a large database including medical records and pharmacy invoice data to explore use of drugs in OA patients in the period 2006-2010: non-steroidal anti-inflammatory drugs (NSAIDs), Symptomatic Slow Acting Drugs for OA (SYSADOA), COX-2 inhibitors (COX2i), opioids, and analgesics (paracetamol and metamizol).

Methods:

We screened the SIDIAP Database (www.sidiap.org) to identify those aged 40 years or older with a new diagnosis of OA, and ascertained use of NSAIDs, COX2i, SYSADOA, opioids, and analgesics in the period 2006-2010. SIDIAP contains anonymised medical records and pharmacy invoice data of a representative >4.9 million people in Catalonia (North-East Spain). We estimated prevalence (and 99% Confidence Intervals) of use of these drugs and their combinations, and the incidence (and 99%CI) of new users among newly diagnosed OA patients in the study period assuming a Poisson distribution.

Results:

We identified 238,536 patients with an incident clinical diagnosis of OA. Among these, 128,655(53.9%) were treated with 3 or more drugs, and 60,740(25.5%) with 2 drugs. The most common combinations among the latter were:1.oral NSAID+analgesic, 2.topical NSAID+analgesic, and 3.oral NSAID+SYSADOA. Besides, 34,802(14.6%) patients received only 1 drug (the 3 most common being, in descending order: oral NSAID, analgesic and SYSADOA), and 14,339(6.0%) were not on pharmacologic treatment. Incidence of use of oral and topical NSAIDs, SYSADOA and analgesics decreased slowly from 2006 to 2010, while opioids increased continuously in the same period [Figure]. Incidence of use of COX2i rose steeply in the period 2006-2008, and continued increasing slowly from then onwards [Figure].

Conclusion:

About 75% of OA patients are treated with at least 2 drugs, and more than half receive 3 or more. Incidence of use of commonly used drugs (such as analgesics and topical NSAIDs) is decreasing, whilst prescriptions of opioids increase. In addition, use of COX2i continues to grow, yet more slowly after 2008, when warnings on the detrimental effects of COX2i on cardiovascular health were published. These data suggest that patients with OA are often polymedicated, and that current guidelines are poorly implemented in general practice. This has potential implications not only in terms of health care costs but also for patient safety.

Figure. Incidence rates (and 99%CI) of newly indicated drugs for OA in the period 2006-2010: a) The most commonly used analgesic (Paracetamol), SYSADOAs and the most commonly prescribed opioid (tramadol) [top]; b) Topical and oral NSAIDs, Paracetamol (alone and combined with other drugs), and Opioids; c) Cox 2 inhibitors


Disclosure:

D. Prieto-Alhambra,
None;

R. Morros,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-drug-combinations-in-patients-with-osteoarthritis-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology